See more : Mandarin Hotel Public Company Limited (MANRIN.BK) Income Statement Analysis – Financial Results
Complete financial analysis of RVL Pharmaceuticals plc (OSMT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RVL Pharmaceuticals plc, a leading company in the Biotechnology industry within the Healthcare sector.
- BAE Systems plc (BSP.DE) Income Statement Analysis – Financial Results
- Archimedes Tech SPAC Partners Co. (ATSPT) Income Statement Analysis – Financial Results
- Suzhou Douson Drilling & Production Equipment Co.,Ltd. (603800.SS) Income Statement Analysis – Financial Results
- Launch Technologies Co., Ltd. (8420.TWO) Income Statement Analysis – Financial Results
- Abri SPAC I, Inc. (ASPAU) Income Statement Analysis – Financial Results
RVL Pharmaceuticals plc (OSMT)
About RVL Pharmaceuticals plc
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 49.72M | 17.50M | 27.76M | 240.03M | 263.70M | 245.75M | 218.46M |
| Cost of Revenue | 9.46M | 3.62M | 3.29M | 111.63M | 140.08M | 125.19M | 125.62M |
| Gross Profit | 40.27M | 13.88M | 24.47M | 128.40M | 123.62M | 120.56M | 92.84M |
| Gross Profit Ratio | 80.98% | 79.33% | 88.14% | 53.49% | 46.88% | 49.06% | 42.50% |
| Research & Development | 3.97M | 6.93M | 13.39M | 32.32M | 43.69M | 42.69M | 29.06M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 81.98M | 87.46M | 72.82M | 93.03M | 74.24M | 56.95M | 65.96M |
| Other Expenses | 6.26M | -1.33M | -48.00K | 884.00K | 664.39K | -4.52M | 168.73K |
| Operating Expenses | 85.95M | 94.39M | 86.21M | 125.35M | 117.94M | 99.64M | 95.02M |
| Cost & Expenses | 95.40M | 98.01M | 89.50M | 236.98M | 258.02M | 224.83M | 220.64M |
| Interest Income | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.11M | 4.02M | 4.10M | 18.21M | 20.79M | 29.05M | 20.19M |
| Depreciation & Amortization | 9.49M | 6.84M | 20.98M | 57.02M | 81.57M | 46.45M | 23.59M |
| EBITDA | -36.19M | -73.67M | -40.76M | 60.95M | -664.39M | 62.85M | 21.58M |
| EBITDA Ratio | -72.78% | -420.94% | -146.83% | 25.39% | 33.34% | 25.57% | 9.88% |
| Operating Income | -45.68M | -80.51M | -61.74M | 3.94M | -98.54M | -52.07M | -32.05M |
| Operating Income Ratio | -91.87% | -460.03% | -222.40% | 1.64% | -37.37% | -21.19% | -14.67% |
| Total Other Income/Expenses | -6.03M | 315.00K | -33.05M | -301.96M | -20.13M | -33.57M | -20.02M |
| Income Before Tax | -51.71M | -82.53M | -94.80M | -298.02M | -118.66M | -85.64M | -52.07M |
| Income Before Tax Ratio | -104.00% | -471.60% | -341.46% | -124.16% | -45.00% | -34.85% | -23.83% |
| Income Tax Expense | -20.00K | 315.00K | -5.78M | -27.12M | -8.98M | -40.49M | -10.25M |
| Net Income | -51.69M | -82.85M | -89.01M | -270.90M | -109.68M | -45.15M | -41.82M |
| Net Income Ratio | -103.96% | -473.40% | -320.63% | -112.86% | -41.59% | -18.37% | -19.14% |
| EPS | -0.58 | -1.23 | -1.47 | -5.17 | -2.42 | -1.05 | -0.98 |
| EPS Diluted | -0.58 | -1.23 | -1.47 | -5.17 | -2.42 | -0.98 | -0.98 |
| Weighted Avg Shares Out | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 42.86M | 42.85M |
| Weighted Avg Shares Out (Dil) | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 45.86M | 42.85M |
Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript
Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021
Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering
OSMT Stock: Why It Fell By Over 35% This Week
Here's why Osmotica Pharmaceuticals is down 35% on Thursday
Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million
Source: https://incomestatements.info
Category: Stock Reports